Status:

COMPLETED

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults

Lead Sponsor:

Crucell Holland BV

Conditions:

Rabies

Eligibility:

All Genders

18-55 years

Phase:

PHASE2

Brief Summary

Study design: Single-blind (subject and observer-blinded), active-controlled, randomized \[6:2:1:2:1; CL184 + purified vero cell rabies vaccine (PVRV) vs. human rabies immune globulin (HRIG) + PVRV v...

Detailed Description

This study was designed to explore and obtain further safety and RVNA data on CL184 in comparison to HRIG and placebo as part of a classical post-exposure prophylaxis (PEP) regimen. This regimen will ...

Eligibility Criteria

Inclusion

  • Male or female subject aged ≥18 to ≤55 years
  • Subjects free of obvious health-problems or with stable conditions or medications
  • Body mass index between ≥18 to ≤30 kg/m2
  • Abstinence from sexual intercourse or use of adequate contraception from the date of screening up to Day 90
  • Male subjects must agree that they will not donate sperm from the first check-in until Day 90
  • Subject signed written informed consent

Exclusion

  • Prior history of active or passive rabies immunization
  • Clinically significant acute illness or infection including fever (≥38 °C) within 2 weeks before first dosing
  • History and/or family history of clinically significant immunodeficiency or auto-immune disease
  • Planned immunization with live vaccines during the coming 3 months after first dosing
  • Chronic (longer than 14 days) administration of immunosuppressants or other immune-modifying drugs within 6 months before the first dose of investigational medicinal product

Key Trial Info

Start Date :

December 1 2011

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2012

Estimated Enrollment :

240 Patients enrolled

Trial Details

Trial ID

NCT01228383

Start Date

December 1 2011

End Date

December 1 2012

Last Update

April 10 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Lotus House, Vasanth Nagar

Bangalore, Karnataka, India, 560 052

Rabies Virus Neutralizing Activity and Safety of CL184, a Monoclonal Antibody Cocktail, in Simulated Rabies Post-Exposure Prophylaxis in Healthy Adults | DecenTrialz